Abstract
In an infection with an Enterobacter sp. isolate producing Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1 in the United States, recognition of the molecular basis of carbapenem resistance allowed for successful treatment by combining ceftazidime-avibactam and aztreonam. Antimicrobial synergy testing and therapeutic drug monitoring assessed treatment adequacy.
Keywords:
KPC; NDM; aztreonam; carbapenemase; ceftazidime-avibactam.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use
-
Azabicyclo Compounds / therapeutic use
-
Aztreonam / therapeutic use
-
Bacteremia* / drug therapy
-
Bacterial Proteins
-
Ceftazidime / therapeutic use
-
Drug Combinations
-
Enterobacter
-
Humans
-
Klebsiella Infections* / drug therapy
-
Klebsiella pneumoniae / genetics
-
Microbial Sensitivity Tests
-
United States
-
beta-Lactamases / genetics
Substances
-
Anti-Bacterial Agents
-
Azabicyclo Compounds
-
Bacterial Proteins
-
Drug Combinations
-
avibactam, ceftazidime drug combination
-
Ceftazidime
-
beta-Lactamases
-
beta-lactamase NDM-1
-
carbapenemase
-
Aztreonam